Malin’s Value Soars with Poseida Acquisition by Roche

Malin (MLLNF) has released an update.

Malin Corporation’s investee company, Poseida Therapeutics, is set to be acquired by Roche, leading to a substantial boost in Malin’s equity value and prompting a halt on its previously announced tender offer. The transaction is expected to bring Malin an initial $106.5 million, with further potential earnings, significantly increasing the company’s estimated intrinsic equity value per share. Malin plans to reassess its capital return strategy following this lucrative development.

For further insights into MLLNF stock, check out TipRanks’ Stock Analysis page.